Balanced news tone
News Sentiment
GILD sentiment intelligence
Gilead Sciences Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.
Weighted score
54
Balanced news tone
52 relevant articles
News tone and price action are not far from neutral.
86/100 classification confidence.
directly relevant articles
high-authority source matches
-1.1% over one week, +4.1% over four weeks, trend inactive, and materially above fair value.
GILD (NASDAQ: GILD) holder plans 3,000-share common stock sale
Market Reaction
Balanced read
News tone and price action are not far from neutral.
Primary event
Market update
86/100 classification
One-week reaction
-1.1%
Price digesting
Trend fit
Trend inactive
4.1% over four weeks
Fair value
36.1%
Materially above fair value
Sentiment Mix
Positive, neutral, negative
Positive
17
Neutral
26
Negative
9
Relevance
Why the article matched
Sources
Coverage mix
Event Lens
What the news is about
Sentiment Trail
Score over time
Above 50
Neutral zone
Below 50
News Tape
Relevant headlines
Market source
Direct company coverage
Will Trodelvy’s First-Line TNBC Approval Redefine Gilead Sciences’ (GILD) Oncology-Led Investment Narrative?
- Tone
- Neutral 50/100
- Event
- Regulatory and legal
- Published
- 26 Jun 2026 07:00
- Source
- Market source
Market source
Direct company coverage
Could This FDA Milestone Unlock Gilead’s (GILD) Next Big Growth Driver?
- Tone
- Positive 66/100
- Event
- Market update
- Published
- 22 Jun 2026 07:00
- Source
- Market source
Quiver Quantitative
Direct company coverage
Gilead Sciences Stock (GILD) Opinions on Recent Congressional Insider Activity
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 22 Jun 2026 07:00
- Source
- Quiver Quantitative
The Globe and Mail
Direct company coverage
The Zacks Analyst Blog Highlights Gilead Sciences, Merck and GSK
- Tone
- Neutral 50/100
- Event
- Analyst action
- Published
- 17 Jun 2026 07:00
- Source
- The Globe and Mail
Market source
Direct company coverage
Gilead Sciences (GILD) Stock Falls Amid Market Uptick: What Investors Need to Know
- Tone
- Negative 22/100
- Event
- Market update
- Published
- 15 Jun 2026 07:00
- Source
- Market source
Market source
Direct company coverage
How Is Gilead Sciences's Stock Performance Compared to Other Healthcare Stocks
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 02 Jun 2026 07:00
- Source
- Market source
Reuters
Direct company coverage
Gilead's drug wins first-ever US approval for deadly liver infection
- Tone
- Neutral 50/100
- Event
- Regulatory and legal
- Published
- 26 May 2026 07:00
- Source
- Reuters
Market source
Direct company coverage
Is It Time To Reassess Gilead Sciences (GILD) After Strong Multi Year Share Price Gains
- Tone
- Positive 82/100
- Event
- Market update
- Published
- 23 May 2026 07:00
- Source
- Market source
Investing.com
Direct company coverage
Gilead Sciences stock rises after FDA approves HDV treatment
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 22 May 2026 07:00
- Source
- Investing.com
TIKR.com
Direct company coverage
Gilead Sciences Just Told Investors What to Watch Before December 23. Here’s What the Data Says About GILD Stock.
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 15 May 2026 07:00
- Source
- TIKR.com
Market source
Direct company coverage
Gilead Sciences Inc. (GILD): Growing Popularity as Defensive Stock
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 26 Apr 2026 07:00
- Source
- Market source
TradingView
Direct company coverage
Bristol Myers vs Gilead Sciences: Which Biotech Stock Is a Better Bet Now?
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 21 Apr 2026 07:00
- Source
- TradingView
TIKR.com
Direct company coverage
Gilead Sciences Deploys $16 Billion in 60 Days: Is GILD Stock Undervalued for 2026?
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 21 Apr 2026 07:00
- Source
- TIKR.com
Investing.com
Direct company coverage
Gilead expands HIV prevention drug access to 3 million people
- Tone
- Positive 66/100
- Event
- Market update
- Published
- 14 Apr 2026 07:00
- Source
- Investing.com
TradingKey
Direct company coverage
Gilead's Stock Price is Expected to Rise to $160,Gilead’s $5 Billion Tubulis Deal Could Reshape the Cancer Drug Market of America
- Tone
- Neutral 50/100
- Event
- Deals and strategy
- Published
- 08 Apr 2026 07:00
- Source
- TradingKey
TIKR.com
Direct company coverage
Gilead Has Fallen 11% From Its 52-Week High. Is Now the Time to Buy GILD?
- Tone
- Positive 66/100
- Event
- Market update
- Published
- 06 Apr 2026 07:00
- Source
- TIKR.com
Market source
Direct company coverage
Here is What to Know Beyond Why Gilead Sciences, Inc. (GILD) is a Trending Stock
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 19 Mar 2026 07:00
- Source
- Market source
Bloomberg.com
Direct company coverage
Gilead to Buy US Biotech Arcellx for Up to $7.8 Billion
- Tone
- Positive 66/100
- Event
- Market update
- Published
- 23 Feb 2026 08:00
- Source
- Bloomberg.com
TradingView
Direct company coverage
Can Gilead's HIV Portfolio Sustain Its Growth Trend in 2026?
- Tone
- Positive 66/100
- Event
- Market update
- Published
- 13 Feb 2026 08:00
- Source
- TradingView
Market source
Direct company coverage
Gilead Sciences (GILD) Stock Declines While Market Improves: Some Information for Investors
- Tone
- Negative 34/100
- Event
- Market update
- Published
- 05 Jan 2026 08:00
- Source
- Market source
The Motley Fool
Direct company coverage
How to Buy Gilead Sciences Stock (GILD)
- Tone
- Positive 66/100
- Event
- Market update
- Published
- 31 Dec 2025 08:00
- Source
- The Motley Fool
TIKR.com
Direct company coverage
Who Owns Gilead Sciences? Top Shareholders and Recent Insider Trades
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 11 Dec 2025 08:00
- Source
- TIKR.com